To include your compound in the COVID-19 Resource Center, submit it here.

Management tracks: Akari, Turnstone, Iconic

Autoimmune and inflammatory disease company Akari Therapeutics plc (NASDAQ:AKTX) named David Horn Solomon CEO, effective Aug. 28. He was managing partner at Sund Capital, and was previously CEO of Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) and Bionor Pharma ASA which

Read the full 399 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE